Quarterly Result30 Jan 2026, 01:45 pm
Dr. Lal PathLabs Announces 10.6% Revenue Growth in Q3 FY26, PAT at Rs 91 Cr
AI Summary
Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced its financial results for the quarter ended December 31, 2025. The company reported a 10.6% increase in revenue for Q3 FY26 and a 10.8% increase for the nine months ended Dec’25. The EBITDA before exceptional items for Q3 FY26 increased by 16.3% with a margin of 27.2%. The P&L for Q3 FY26 includes an exceptional impact of Rs 30.1 Cr on account of Labour codes. The company declared an interim dividend of Rs. 3.5 per share for Q3 FY26. The cash and bank balances as on 31‘ Dec, 2025 is Rs. 1,411 Cr.
Key Highlights
- Revenue increased by 10.6% in Q3 FY26 and by 10.8% for nine months ended Dec’25
- EBITDA (before exceptional items) for Q3 FY26 increased by 16.3% with a margin of 27.2%
- P&L for Q3 FY26 includes an exceptional impact of Rs 30.1 Cr on account of Labour codes
- PAT for Q3 FY26 is Rs 91 Cr. with a margin for of 13.9%
- Interim Dividend of Rs. 3.5 per share for Q3 FY26